DocGo, Inc. Hits 52-Week Low of $0.97 Amid Ongoing Struggles

DocGo, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 0.97 as of November 11, 2025. This decline marks a significant downturn for the stock, which has experienced a staggering 65.62% drop in value over the past year, contrasting sharply with the S&P 500's performance of 13.96% during the same period.
The company's financial metrics reveal a challenging landscape, with a negative operating profit decline of 478.14% reported in June. DocGo has faced consecutive quarters of negative results, contributing to a concerning trend in its financial health. The company's return on equity stands at -9.71%, and its price-to-book ratio is at 0.52, indicating potential undervaluation relative to its assets.

Additionally, the company's promoters have reduced their stake by 2.1% in the last quarter, now holding 4.95% of the company, which may reflect waning confidence in its future prospects. With net sales at a low of USD 80.42 million and a return on capital employed (ROCE) of -5.98%, DocGo continues to face significant challenges in its market position.